The Biden administration must follow through on its promises, and Congressional leaders must do more to push through bipartisan biosimilar policies to encourage better adoption and lower drug costs, according to Julie M. Reed, the executive director of the Biosimilars Forum.
The Biden administration must follow through on its promises, and Congressional leaders must do more to push through bipartisan biosimilar policies to encourage better adoption and lower drug costs, according to Julie M. Reed, the executive director of the Biosimilars Forum.
Transcript
What sort of policy initiatives should legislators and the FDA be putting a greater focus on?
Reed: This is really the critical year, and we need the administration to follow up on the President Biden's executive order to do more with biosimilars; it's almost a 1-year anniversary. So, we need CMS to get some biosimilar programs out there. We've been talking for a long time and they're leaving cost savings on the table. [It's] really important, especially now.
So, that's one piece of it; the administration needs to act and follow up. In Congress, biosimilars have been a bipartisan solution for a number of yours. But unfortunately, politics have stopped some of our ideas and that are supported, as I mentioned, by both sides in the House and in the Senate. [Reimbursing at] ASP [average sales price] plus 8%, shared savings, and $0 copay. Those things need to happen, especially with the [adalimumab biosimilar] launches next year and [the biosimilars] launching in ophthalmology. We've launched a interchangeable insulin biosimilar. All these products are coming to fruition, yet patients don't have access to them.
And so, we need the administration and Congress to do something. The other piece, about the FDA, we, as stakeholders and partners with the FDA, have to get the BsUFA [Biosimilar User Fee Amendment], the super 3 pac that's critical, and then we have to partner with the FDA to to evolve the program through the science regulatory science program. So, that's really key. And then continue, like I said, our partnerships with the other agencies, like the FTC, the FDA, and CMS, to do everything we can to make us more successful.
Webinar Addresses Solutions to Improve Adalimumab Biosimilar Uptake
March 18th 2024Government policies, including those related to prescribing incentives and interchangeability, need to be reworked to encourage biosimilar adoption and create meaningful savings for health systems, according to speakers at a recent webinar.
A New Chapter: How 2023 Will Shape the US Biosimilar Space for 2024 and Beyond
December 31st 2023On this episode of Not So Different, Cencora's Brian Biehn and Corey Ford take a look back at major policy and regulatory advancements in 2023 and how these changes will alter the space going forward.
The Subcutaneous Revolution: Zymfentra and the Future of IBD Care With Dr Andres Yarur
December 17th 2023On this episode of Not So Different, Andres Yarur, MD, a researcher and associate professor of medicine at Cedars-Sinai Medical Center, discusses the significance of the FDA approval for Zymfentra, the world's first subcutaneous infliximab product, for patients with inflammatory bowel disease (IBD).
BioRationality: EMA Announces Readiness to Waive Comparative Efficacy Studies of Biosimilars
March 4th 2024Sarfaraz K. Niazi, PhD, takes a look at the European Medicines Agency's (EMA) announcement that it will investigate whether comparative efficacy tests should be needed for a biosimilar to receive regulatory approval.